Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $2.6 million.

  • Serina Therapeutics' Net Cash Flow rose 19062.17% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 22395.31%. This contributed to the annual value of -$3.9 million for FY2024, which is 15569.35% down from last year.
  • According to the latest figures from Q3 2025, Serina Therapeutics' Net Cash Flow is $2.6 million, which was up 19062.17% from $1.7 million recorded in Q2 2025.
  • Serina Therapeutics' 5-year Net Cash Flow high stood at $8.8 million for Q2 2023, and its period low was -$2.9 million during Q3 2024.
  • Over the past 5 years, Serina Therapeutics' median Net Cash Flow value was $116000.0 (recorded in 2021), while the average stood at $447789.5.
  • Within the past 5 years, the most significant YoY rise in Serina Therapeutics' Net Cash Flow was 336850.39% (2023), while the steepest drop was 38347.46% (2023).
  • Quarter analysis of 5 years shows Serina Therapeutics' Net Cash Flow stood at -$147000.0 in 2021, then soared by 221.77% to $179000.0 in 2022, then crashed by 78.77% to $38000.0 in 2023, then skyrocketed by 1050.0% to $437000.0 in 2024, then soared by 497.03% to $2.6 million in 2025.
  • Its Net Cash Flow stands at $2.6 million for Q3 2025, versus $1.7 million for Q2 2025 and $595000.0 for Q1 2025.